Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in Nat Med Retrieve available abstracts of 55 articles: HTML format

Single Articles

July 2024
1. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
   Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
   Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
   PubMed    
   
   
   
2. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
   Challenges to identifying risk versus protective factors in Alzheimer's disease.
   Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
   PubMed    
   
   
   
3. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
   Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
   Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
   PubMed     Abstract available
   
   
   June 2024
4. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
   Revised criteria for the diagnosis and staging of Alzheimer's disease.
   Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
   PubMed    
   
   
   
5. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
   Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
   Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
   PubMed    
   
   
   May 2024
6. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
   p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
   Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
   PubMed     Abstract available
   
   
   
7. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
   APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
   Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
   PubMed     Abstract available
   
   
   
8. XU Q, Liang Z, Huang Y
   APOE4 homozygosity is a new genetic form of Alzheimer's disease.
   Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
   PubMed    
   
   
   March 2024
9. O'LEARY K
   A timeline of biomarker changes before Alzheimer's disease.
   Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
   PubMed    
   
   
   February 2024
10. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    PubMed     Abstract available
    
    
    January 2024
11. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    PubMed    
    
    
    
12. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    PubMed     Abstract available
    
    
    
13. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    PubMed    
    
    
    December 2023
14. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    PubMed    
    
    
    November 2023
15. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    PubMed    
    
    
    October 2023
16. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    PubMed    
    
    
    September 2023
17. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    PubMed    
    
    
    
18. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    PubMed     Abstract available
    
    
    
19. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    PubMed     Abstract available
    
    
    August 2023
20. 
    Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    PubMed    
    
    
    
21. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    PubMed     Abstract available
    
    
    
22. 
    A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    PubMed    
    
    
    
23. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    PubMed     Abstract available
    
    
    
24. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    PubMed     Abstract available
    
    
    July 2023
25. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    PubMed    
    
    
    
26. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    PubMed     Abstract available
    
    
    
27. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    PubMed    
    
    
    June 2023
28. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    PubMed     Abstract available
    
    
    May 2023
29. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    PubMed     Abstract available
    
    
    
30. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    PubMed    
    
    
    
31. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    PubMed     Abstract available
    
    
    April 2023
32. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    PubMed     Abstract available
    
    
    December 2022
33. ASHTON NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, et al
    Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.
    Nat Med. 2022 Dec 1. doi: 10.1038/s41591-022-02074.
    PubMed     Abstract available
    
    
    
34. HORIE K, Barthelemy NR, Spina S, VandeVrede L, et al
    CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
    Nat Med. 2022;28:2547-2554.
    PubMed     Abstract available
    
    
    November 2022
35. MOUTINHO S
    The long road to a cure for Alzheimer's disease is paved with failures.
    Nat Med. 2022;28:2228-2231.
    PubMed    
    
    
    
36. OSSENKOPPELE R, Pichet Binette A, Groot C, Smith R, et al
    Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Nat Med. 2022;28:2381-2387.
    PubMed     Abstract available
    
    
    
37. 
    Amyloid-beta and tau PET scans predict clinical progression in cognitively unimpaired people.
    Nat Med. 2022;28:2267-2268.
    PubMed    
    
    
    September 2022
38. 
    Toward inflammation-free therapeutics in Alzheimer's disease.
    Nat Med. 2022 Sep 8. pii: 10.1038/s41591-022-01972.
    PubMed    
    
    
    
39. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022;28:1965.
    PubMed    
    
    
    
40. JUNG H, Lee SY, Lim S, Choi HR, et al
    Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein.
    Nat Med. 2022;28:1802-1812.
    PubMed     Abstract available
    
    
    August 2022
41. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022 Aug 11. pii: 10.1038/s41591-022-01925.
    PubMed     Abstract available
    
    
    July 2022
42. SCHINDLER SE, Karikari TK
    Comorbidities confound Alzheimer's blood tests.
    Nat Med. 2022 Jul 4. pii: 10.1038/s41591-022-01875.
    PubMed    
    
    
    
43. MIELKE MM, Dage JL, Frank RD, Algeciras-Schimnich A, et al
    Performance of plasma phosphorylated tau 181 and 217 in the community.
    Nat Med. 2022;28:1398-1405.
    PubMed     Abstract available
    
    
    February 2022
44. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.
    PubMed    
    
    
    September 2021
45. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    PubMed     Abstract available
    
    
    
46. PERLMUTTER JS
    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.
    PubMed    
    
    
    
47. CUMMINGS J
    Why aducanumab is important.
    Nat Med. 2021;27:1498.
    PubMed    
    
    
    August 2021
48. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.
    PubMed    
    
    
    July 2021
49. RABINOVICI GD
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.
    PubMed    
    
    
    June 2021
50. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    PubMed     Abstract available
    
    
    
51. HANSSON O
    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    PubMed     Abstract available
    
    
    May 2021
52. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    PubMed     Abstract available
    
    
    April 2021
53. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    PubMed     Abstract available
    
    
    January 2021
54. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.
    PubMed    
    
    
    November 2020
55. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.